Dravet syndrome is an epileptic condition with a 15 to 20 percent mortality rate and resistant to current medications. Tel Aviv University researchers have discovered that the DHODH gene is key to triggering such adverse neural activity and that Terflunomide … Continue reading →

Tel Aviv University scientists have linked gene Gtf2i to Williams Syndrome (WS) and the thinning of the myelin layer that protects neurons in the brain. In lab tests they managed to reverse some WS symptoms using the FDA-approved antihistamine clemastine … Continue reading →

I reported previously (Dec 2015) on Israel’s Betalin Therapeutics, which has developed an insulin-producing micro pancreas that can be implanted into the body of diabetics. Betalin has since won startup awards in Tel Aviv and China and has just raised … Continue reading →

The US FDA has approved the generic naloxone hydrochloride nasal spray developed by Israel’s Teva. Commonly known as Narcan, the medication can stop or reverse the effects of an opioid overdose. The emergency treatment can be administered even by those … Continue reading →

I reported previously (see here) on the NeuroAD cranial device from Israel’s Neuronix. It already has European approval and is now being urgently reviewed in the FDA’s Expedited Access Pathway program for breakthrough devices that target vital unmet needs. https://www.medpagetoday.com/neurology/alzheimersdisease/78739

I reported previously (see here) on Israel’s Sight Diagnostics’ device that can perform full blood tests using just a few drops of blood.  Sight Diagnostics has just completed a successful trial which should help it obtain US FDA approval. The … Continue reading →

I reported previously (2nd Sep) when retired surgeon Norman Rosenbaum was awarded by UK PM Theresa May for helping to buy 11 ambulances for Israeli emergency service Magen David Adom. Norman has just fundraised his 12th ambulance for MDA who … Continue reading →

A recent study of Go-Less Men (EFLA940 – an extract from pumpkin seeds) to be effective in the treatment of symptoms of BHP (Benign Prostatic Hyperplasia). Go-Less is marketed by Israel-founded Frutarom. A previous study showed Go-Less to relieve incontinence … Continue reading →

At Israel’s Weizmann Institute there are over 60 research groups focusing on beating cancer and over 40% of the Institute’s life sciences research is cancer-related. https://www.youtube.com/watch?v=KegBnx3WNVo